Current Status
Not Enrolled
Price
$59.00
Get Started
or
0
Hours Total
0
Hours Pharmacology

#100 MCAS Part 2 – Mast Cell Activation to Mastocytosis Assessment & Therapy

Current Status
Not Enrolled
Price
$59.00
Get Started
or

Abstract

Part 1 of this series went into histamine biology and management deeply. In this follow-up CE we will look more closely at the spectrum of mast cell disorders ranging from major pathologies in the mastocytosis family through all the functional mast cell activation syndromes. Causes, aggravations, therapies (natural and pharmacologic), and management will be addressed.

Objectives:

Define Mast Cell Disorders in the spectrum from “Activation Syndromes to Mastocytosis”
Review mast cell biology
Describe the differential diagnosis in mastocytosis
Define the common triggers of mast cell activation

CME Outline:

1. Definitions and Pathology
2. Testing (and it’s limitations)
3. Implications of test abnormalities
4. Triggers of MCAS
5. Relevant pharmacology (Mastocytosis)
6. Relevant pharmacology(MCAS)

Course Tags:

1 thought on “#100 MCAS Part 2 – Mast Cell Activation to Mastocytosis Assessment & Therapy”

  1. infdzsleuth@gmail.com

    Hi Dr A. Regarding #100 MCAS Part 2: Unfortunately, I now find myself with a particularly severe case of gastrointestinal “long covid” as defined in a report on GI complications by the Harvard Coronavirus Visualization Team. Initially I presented with almost none of the usual signs and symptoms of covid. 8 weeks after initial onset, another doc ordered an EGD/etc. which revealed Eosinophilic Esophagitis. I’m hoping that you’ll be able to cover covid as a strong trigger of acute Mastocytosis with concomitant Eosinophilia in your #100 webinar. The prognosis does not look good, as this condition appears to be associated with significant levels of morbidity and mortality. Other signs/Sx included acute liver damage (Harvard) with receding hepatomegaly (also likely eosinophilic according to other journal lit), acute but receding kidney damage (Johns Hopkins), delayed development of chronic pancreatitis (Harvard), severe/painful/nearly constant abdominal bloating (Harvard), and almost daily pseudo-blockages of the small intestine (Harvard). Fortunately, our medicine offers some possible treatment options that are not available elsewhere, but I’m not fooling myself by thinking this guarantees a good outcome. It appears that G.I. covid and kidney damage are far more prevalent than the medical community at-large is willing to admit (according to statistics published by both Harvard and Johns Hopkins). I’ve also seen a few vague references in peer reviewed literature to covid vaccines also causing most or all of these same G.I. signs and symptoms. However, the public really needs to know more than the powers-that-be are willing to publicize about gastrointestinal covid and its potentially serious complications, including death. I’m a board review client from years ago. My friend and Doctor Mary Reker referred me to your #100 MCAS Part 2 webinar. See ya there. Glad to see you are still putting out top-quality information to keep our people on the cutting edge of medicine.

Leave a Reply

Scroll to Top